As of Friday close, Ventyx Biosciences Inc.’s (NASDAQ:VTYX) stock was up $1.18, moving up 3.96 percent to $30.98. The average number of shares traded per day over the past five days has been 728,320 shares. 1 time new highs have been achieved over the past 5 days, with a -$2.42 fall in that time frame. In the last twenty days, the average volume was 588,125, while in the previous 50 days, it was 755,428.
Since last month, VTYX stock retreated -13.70%. Shares of the company fell to $29.35 on 08/16/23, the lowest level in the past month. A 52-week high of $47.25 was reached on 03/03/23 after having rallying from a 52-week low of $19.73. Since the beginning of this year, VTYX’s stock price has dropped by -5.52% or -$1.81, and marked a new high 16 times. However, the stock has declined by -34.43% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
VTYX stock investors should be aware that Ventyx Biosciences Inc. (VTYX) stock had its last reported insider trading activity 11 days ago on Aug 08. Sandborn William J., the of the company, disposed of 3,494 shares for $32.86 on Aug 08. It resulted in a $114,810 divestment by the insider. Mohan Raju sold 30,000 shares at an average price of $33.52 on Aug 07. The insider now owns 1,512,911 shares following the transaction. On Aug 03, Chief Business Officer Krueger Christopher W sold 15,000 shares at $35.59 apiece. The transaction was valued at $533,797.
Financial Health
In the three months ended June 29, Ventyx Biosciences Inc.’s quick ratio stood at 17.30, while its current ratio was 17.30, showing that the company is able to pay off its debt.
While analysts expected Ventyx Biosciences Inc. to report -$0.71 quarterly earnings, the actual figure was -$0.91 per share, beating the consensus estimate by -28.20%. The liabilities of Ventyx Biosciences Inc. were 20.96 million at the end of its most recent quarter ended June 29, and its total debt was $1.36 million. The value of shareholders’ equity is $58.89 million.
Technical Picture
This quick technical analysis looks at Ventyx Biosciences Inc.’s (VTYX) price momentum. With a historical volatility rate of 55.63%, the RSI 9-day stood at 36.51% on 18 August.
With respect to its five-day moving average, the current Ventyx Biosciences Inc. price is down by -7.25% percent or -$2.42. At present, VTYX shares trade -13.37% below its 20-day simple moving average and -11.00% percent below its 100-day simple moving average. However, the stock is currently trading approximately -12.66% below its SMA50 and -4.29% below its SMA200.
Stochastic coefficient K was 10.71% and Stochastic coefficient D was 8.64%, while ATR was 1.78. Given the Stochastic reading of 20.35% for the 14-day period, the RSI (14) reading has been calculated as 38.79%. As of today, the MACD Oscillator reading stands at -1.72, while the 14-day reading stands at -3.01.
Analyst Ratings
Ventyx Biosciences Inc. (VTYX) has been rated Buy by analysts. According to 0 brokerage firms, VTYX is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Ventyx Biosciences Inc. stock as buy, with 11 recommending it as overweight.
With a median target price of $56.00, the current consensus forecast for the stock is $48.00 – $77.00. Based on these forecasts, analysts predict Ventyx Biosciences Inc. (VTYX) will achieve an average price target of $57.73.
